189 related articles for article (PubMed ID: 22621866)
1. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
[TBL] [Abstract][Full Text] [Related]
2. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.
Kosinski JR; Hubert J; Carrington PE; Chicchi GG; Mu J; Miller C; Cao J; Bianchi E; Pessi A; Sinharoy R; Marsh DJ; Pocai A
Obesity (Silver Spring); 2012 Aug; 20(8):1566-71. PubMed ID: 22421924
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle.
ThanThan S; Saito T; Yannaing S; Zhao H; Nakashima K; Kuwayama H
Domest Anim Endocrinol; 2012 Apr; 42(3):155-64. PubMed ID: 22154917
[TBL] [Abstract][Full Text] [Related]
4. DPP-IV-resistant, long-acting oxyntomodulin derivatives.
Santoprete A; Capitò E; Carrington PE; Pocai A; Finotto M; Langella A; Ingallinella P; Zytko K; Bufali S; Cianetti S; Veneziano M; Bonelli F; Zhu L; Monteagudo E; Marsh DJ; Sinharoy R; Bianchi E; Pessi A
J Pept Sci; 2011 Apr; 17(4):270-80. PubMed ID: 21294225
[TBL] [Abstract][Full Text] [Related]
5. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
Maida A; Lovshin JA; Baggio LL; Drucker DJ
Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
[TBL] [Abstract][Full Text] [Related]
6. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
[TBL] [Abstract][Full Text] [Related]
8. Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Yannaing S; Kuwayama H
Domest Anim Endocrinol; 2013 Feb; 44(2):70-80. PubMed ID: 23122871
[TBL] [Abstract][Full Text] [Related]
9. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet.
Parlevliet ET; Heijboer AC; Schröder-van der Elst JP; Havekes LM; Romijn JA; Pijl H; Corssmit EP
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E142-7. PubMed ID: 17971509
[TBL] [Abstract][Full Text] [Related]
10. A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.
Bianchi E; Carrington PE; Ingallinella P; Finotto M; Santoprete A; Petrov A; Eiermann G; Kosinski J; Marsh DJ; Pocai A; SinhaRoy R; Pessi A
Bioorg Med Chem; 2013 Nov; 21(22):7064-73. PubMed ID: 24094437
[TBL] [Abstract][Full Text] [Related]
11. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
[TBL] [Abstract][Full Text] [Related]
13. Unraveling oxyntomodulin, GLP1's enigmatic brother.
Pocai A
J Endocrinol; 2012 Dec; 215(3):335-46. PubMed ID: 23019069
[TBL] [Abstract][Full Text] [Related]
14. Oxyntomodulin reduces expression of glucagon-like peptide 1 receptor in the brainstem of chickens.
Moghaddam AG; Yaghoobi MM; Jonaidi H; Mahani MT; Sepehri H
J Anim Physiol Anim Nutr (Berl); 2010 Aug; 94(4):422-8. PubMed ID: 19663977
[TBL] [Abstract][Full Text] [Related]
15. Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Naing SW; Kuwayama H
Domest Anim Endocrinol; 2017 Apr; 59():30-36. PubMed ID: 27888738
[TBL] [Abstract][Full Text] [Related]
16. Action and therapeutic potential of oxyntomodulin.
Pocai A
Mol Metab; 2014 Jun; 3(3):241-51. PubMed ID: 24749050
[TBL] [Abstract][Full Text] [Related]
17. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
18. Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.
Willard FS; Wootten D; Showalter AD; Savage EE; Ficorilli J; Farb TB; Bokvist K; Alsina-Fernandez J; Furness SG; Christopoulos A; Sexton PM; Sloop KW
Mol Pharmacol; 2012 Dec; 82(6):1066-73. PubMed ID: 22930710
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.
Zhang X; Cai Y; Yao Z; Chi H; Li Y; Shi J; Zhou Z; Sun L
Peptides; 2023 Mar; 161():170948. PubMed ID: 36646385
[TBL] [Abstract][Full Text] [Related]
20. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2010 Dec; 80(11):1727-35. PubMed ID: 20735990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
